US regulatory status: approved. Mechanism: Glutathione precursor.
- Mechanism
- Glutathione precursor
pharma · Non Small Cell Lung Cancer · Non-Small Cell Lung Cancer
Hunan Province Tumor
Hunan Province Tumor Hospital
Hunan Province Tumor drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 2
- Drugs
- 5
- Patents
- 0
Hunan Province Tumor pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Hunan Province Tumor drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Hunan Province Tumor in public FDA and regional records.
-
Development asset linked to Hunan Province Tumor in public FDA and regional records.
-
Development asset linked to Hunan Province Tumor in public FDA and regional records.
-
Development asset linked to Hunan Province Tumor in public FDA and regional records.